Results 251 to 260 of about 113,281 (294)

DPP-4 inhibitors

Insulin, 2007
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby lowering glucose levels.
openaire   +2 more sources

Exploration of the DPP-4 inhibitors with a focus on saxagliptin

Expert Opinion on Pharmacotherapy, 2009
Type 2 diabetes (T2DM) has become a worldwide epidemic. Despite a vast array of new compounds to treat T2DM, recommended treatment goals are consistently not achieved in this country thus suggesting a need to increase treatment options.To review the role of DPP-4 inhibitors in treatment of T2DM with an emphasis on saxagliptin.The authors discuss the ...
Jay H, Shubrook, Randall A, Colucci, Frank L, Schwartz   +2 more
openaire   +2 more sources

Novel DPP-4 Inhibitors Against Diabetes

Future Medicinal Chemistry, 2014
DPP-4 specifically degrades the incretin hormone GLP-1 and GIP, both of which are vital modulators of blood glucose homeostasis. Attributed to its potential biological function, DPP-4 inhibition has presently represented an attractive therapeutic strategy for treating diabetes and aroused a significant interest in the pharmaceutical industry.
Yang, Liu, Yongzhou, Hu
openaire   +2 more sources

[DPP-4 inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Now seven compounds of DPP-4 inhibitor are available in Japan. They can be used in any stage of type 2 diabetes if the insulin secretion capacity is retained; first-line choice to third-line choice or combination with insulin therapy. There is no apparent difference in effect of each DPP-4 inhibitor on glycemic control; HbA1c levels are decreased by 0 ...
Shin-Ichi, Harashima, Nobuya, Inagaki
openaire   +1 more source

DPP-4 inhibitors: pharmacological differences and their clinical implications

Expert Opinion on Drug Safety, 2014
Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.An extensive literature search was performed to analyze the pharmacological ...
Ceriello A, SPORTIELLO, Liberata, RAFANIELLO, Concetta, ROSSI, Francesco   +3 more
openaire   +2 more sources

Wildagliptyna – wyjątkowy inhibitor DPP-4

Medycyna Faktów, 2022
Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire   +2 more sources

DPP-4 inhibitors: a patent review (2012 – 2014)

Expert Opinion on Therapeutic Patents, 2014
Dipeptidyl peptidase 4 (DPP-4) is a serine protease, which catalyzes the hydrolytic process of the amide bond X-Ala or X-Pro at the N-terminus of peptides. This enzyme is involved in the degradation of two incretin hormones glucagon-like peptide-1 and glucose-dependent-insulinotropic polypeptide, which increase the production and release of insulin ...
COSTANTE, ROBERTO, STEFANUCCI, AZZURRA, CARRADORI, Simone, Novellino, Ettore, MOLLICA, ADRIANO   +4 more
openaire   +3 more sources

DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

Archives of Pharmacal Research, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire   +2 more sources

Inappropriate Use of DPP-4 Inhibitors

2014
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A, Blank, S, Tamminga, M, Schoch, GG, Steimle, T   +4 more
openaire   +1 more source

How safe are DPP‐4 inhibitors?

Practical Diabetes, 2013
AbstractAbstract.
Laura McCreight, Miles Fisher
openaire   +1 more source